Retreatment with teriparatide: our expertise in three sufferers with extreme secondary osteoporosis.
Osteoporos Int. 2017 04;28(four):1491-1494
Authors: Mana DL, Zanchetta MB, Zanchetta JR
Teriparatide is a drug for the therapy of osteoporosis which is licensed to be used for as much as 24 months. There’s little expertise with retreatment. The intention of this examine was to guage, in three sufferers with extreme secondary osteoporosis, the response to a second cycle of teriparatide relating to bone mineral density (BMD) and osteocalcin. Case 1 : A 62-year-old lady with a number of vertebral fractures has acquired corticoids for a very long time. After beginning teriparatide, her BMD and osteocalcin elevated. She then acquired ibandronate for three years however her BMD declined. After a second therapy with teriparatide, her BMD elevated once more (18%). Case 2 : A 60-year-old lady with extreme osteoporosis in lumbar backbone (LS) (T-score – four.5) had acquired corticoids for a very long time and had celiac illness. After beginning teriparatide, her BMD improved by 11.7%. She then acquired zoledronic acid for 15 months, however bone density decreased, so she was retreated with teriparatide. BMD had a barely greater enhance than after the primary cycle (12.6%). Case three : A 60-year-old lady consulted for osteoporosis (LS T-score – 5.three), a number of fractures, and hyperthyroidism. She began teriparatide with enchancment in BMD (39%). After 24 months, she acquired ibandronate for 1 yr, however as her BMD declined, she was retreated with teriparatide. BMD confirmed a rise of 15%. The indication of a second cycle of therapy with teriparatide in three sufferers was efficient in growing BMD. Extra research are wanted to additional establish the advantages and security of retreatment with teriparatide.
PMID: 27966106 [PubMed – indexed for MEDLINE]